Abstracts tagged "Erdheim-Chester disease and interferons"

Abstract Number: 2010 • 2013 ACR/ARHP Annual Meeting
Erdheim-Chester Disease: A Monocentric Series Of 96 Patients
Julien Haroche¹, Laurent Arnaud¹, Fleur Cohen-Aubart¹, Baptiste Hervier¹, David Saadoun¹, Nathalie Costedoat-Chalumeau², Sophie Besnard³, Kim Heang Ly⁴, Michel Pavic⁵, Jean-Gabriel Fuzibet⁶, Loic Raffray⁷, Laurent Aaron⁸, Pascal Bindi⁹, António Marinho¹⁰, Bjorn Blomberg¹¹, Juan Salvatierra¹², Claudia Dechant¹³, Aude Rigolet¹⁴, François Lifermann¹⁵, Jo Caers¹⁶, Catherine Veyssier-Belot¹⁷, Bertrand Wechsler¹⁸, Lucienne Michaux¹⁹, Giorgio Graziani²⁰ and Zahir Amoura¹, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Internal Medicine, Hopital Cochin, Paris, France, ³Internal Medicine, Pontchaillou University Hospital, Rennes, Rennes, France, ⁴CHU Dupuytren, Limoges, Limoges, France, ⁵Internal Medicine, HIA Desgenettes, Lyon, France, Lyon, France, ⁶Internal Medicine, Internal Medicine, Hôpital de l'Archet 1, CHU de Nice, Nice, France, ⁷Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁸Internal Medicine, Hôpital Jacques Coeur, Bourges, Bourges, France, ⁹Internal Medicine, Department of medicine A, Centre Hospitalier de Verdun, Verdun, France, ¹⁰Unidade de Imunologia Clínica, Porto, Portugal, ¹¹Internal Medicine, University of Bergen, Norway, Bergen, France, ¹²Rheumatology, University Hospital San Cecilio, Granada, Spain, ¹³Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany, ¹⁴Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ¹⁵Internal Medicine, CH Côte d'Argent, Dax, Dax, France, ¹⁶Department of Clinical Hematology, Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman, Liège, Belgium, ¹⁷Internal Medicine, CHI Poissy Saint-Germain-en-Laye, Saint-Germain-en-Laye, France, ¹⁸Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁹Hematology, Cliniques Universitaires Saint-Luc UCL Bruxelles, Bruxelles, Belgium, ²⁰Internal Medicine and Nephrology, Istituto Clinico Humanitas IRCCS, Rozzano-Milano, Italy, Milan, Italy
Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis characterized by an infiltration of foamy CD68+ CD1a- histiocytes. More than 500 cases of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].